gw406381
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Sep 1, 2003 (NCT00279032)
Timeline
Indications
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-(4-ethoxyphenyl)-3-(4-(methylsulfonyl)phenyl)pyrazolo(1,5-b)pyridazine
- gw406381
- gw406381
- gw406381
- gw406381x
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00373243 | Phase 1 | Oct 1, 2005 | GlaxoSmithKline |
| NCT00113308 | Phase 3 | Jun 1, 2005 | GlaxoSmithKline |
| NCT00120900 | Phase 3 | May 1, 2005 | GlaxoSmithKline |
| NCT00114049 | Phase 3 | Dec 1, 2004 | GlaxoSmithKline |
| NCT00279032 | Phase 1 | Sep 1, 2003 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2003 |
1 organizations
Page 1 / 1